Drugs / Adipose tissue-derived Mesenchymal Stromal Cells
Adipose tissue-derived Mesenchymal Stromal Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06592703 | Mar 2025 → Dec 2029 expected | multiple sclerosis | Rennes University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05456243 | Jan 2023 → Apr 2026 | — | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose tissue derived mesenchymal stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05456243 ↗ |
| Known as | A-MSC | “Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)” NCT05456243 ↗ |
| Known as | allo-A-MSC | “allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC )” NCT05456243 ↗ |
| Known as | ASCs | “Adipose tissue-derived Mesenchymal Stromal Cells (ASCs) IT injections” NCT06592703 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived mesenchymal stromal cells” NCT05456243 ↗ |
| Route | Intrathecal | “3 repeated intrathecal (IT) injections of allogenic ASCs every 3 months” NCT06592703 ↗ |